Global Multiple Myeloma Market Size research report 2021 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
This study provides information about the sales and revenue during the historic and forecasted period of (2021 to 2028). Understanding the segments helps in identifying the importance of different factors that aid market growth. Estimations about the CAGR value for specific forecast period, market drivers, market restraints, and competitive strategies are assessed in this Multiple Myeloma Market report.
The global multiple myeloma market size stood at USD 19.48 billion in 2018 and is projected to reach USD 31.00 billion by 2026, exhibiting a CAGR of 6.0% during the forecast period.
Get a Sample Copy of the Report at :
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/102693
Important Features that are under Offering and Key Highlights of the Market Report:
- Detailed overview of the global market share
- Changing market dynamics of the industry
- In-depth market segmentation by Type, Application, etc.
- Historical, current and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape of Multiple Myeloma Market
- Strategies of key players and product offerings
- Potential and niche segments/regions exhibiting promising market growth
Drivers & Restraints
One of the critical market drivers of the global market is the increased prevalence of numerous forms of blood cancers which also includes multiple myeloma. MM, despite considered a rarer cancer type, comprise of a significant number of cancer cases globally and there is an increasing need for efficient and advanced therapeutics.
Key players covered in the global Multiple Myeloma Market research report:
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Bristol Myers Squibb Company
- Amgen Inc.
- ONO PHARMACEUTICAL CO., LTD.
- Janssen Pharmaceuticals, Inc.
- Genentech, Inc. (F. Hoffmann-La Roche Ltd)
- CELGENE CORPORATION (Bristol Myers Squibb Company)
- AbbVie Inc.
- Sanofi
- Karyopharm
- Others
For More Detailed Information, Speak to Our Analyst at :
https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/102693
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are making continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
Major Table of Contents for Multiple Myeloma Market Research Report:
- Introduction
- Executive Summary
- Market Dynamics
- Key Market Growth Insights
- Global Market Analysis, Insights and Forecast, 2017-2028
- North America Market Analysis, Insights and Forecast, 2017-2028
- Europe Market Analysis, Insights and Forecast, 2017-2028
- Asia Pacific Market Analysis, Insights and Forecast, 2017-2028
- The Middle East and Africa Market Analysis, Insights and Forecast, 2017-2028
- Latin America Market Analysis, Insights and Forecast, 2017-2028
- Competitive Landscape
- Global Multiple Myeloma Market Revenue Growth, Industry Share Analysis, By Key Players, 2021
- Company Profiles
- Conclusion
Purchase Full Report at :
https://www.fortunebusinessinsights.com/checkout-page/102693
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected]
the United States, Eu5(the UK, Germany, France, Italy, Spain), China and Japan, was $16.27bn in 2019 and is increasing with a modest CAGR during the study period (2017-2030), according to DelveInsight, a leading company in healthcare analytics and consulting.
In the case of China, higher usage of thalidomide based regimen found in the first-line settingAmong emerging therapies, Bristol Myers Squibb and Bluebird Bio's anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121) is expected to result in significant revenues owing to promising results, one-time dosing and premium pricing in heavily pretreated patientsKey Companies fuelling the Multiple Myeloma market size growth are GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Roche, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer, Takeda, Amgen, AstraZeneca etc.Patent expiry of multiple blockbuster drugs like Revlimid, Pomalyst, Darzalex and Kyprolis is on the lines to expire from 2026 onwards, and this will erode the sales value significantly and the market is expected to decline from 2028 onwards due to cumulative impacts of patent expiry.Download Multiple Myeloma Sample: https://www.delveinsight.com/sample-request/multiple-myeloma-marketThough Multiple Myeloma is not common cancer; still, it is the second most diagnosed blood cancer in the United States.
It is worth highlighting that it is a heterogeneous haematological malignancy in which epidemiology plays an increasingly important role.
Over the past years, intensive clinical and molecular epidemiological research has extended the information about its pathogenesis, risk factors, and prognostic components which aided the approval of new drugs.
Darzalex is also being used by the healthcare experts in combination as doublet, triplet, and quadruplet with existing therapies for the good treatment strategies and better result outcomes and has impacted the MM treatment landscape significantly.
Report includes exhaustive analysis of Multiple Myeloma Pipeline TherapiesIdecabtagene vicleucel (ide-cel): Bristol Myers Squibb and bluebird bioVenetoclax (Venclexta, Venclyxto): AbbVieJNJ-68284528 LCAR-B38M/JNJ-4528): Janssen Research and DevelopmentKeytruda (pembrolizumab): NovartisMelflufen (melphalan flufenamide): OncopeptidesCetrelimab (JNJ-63723283): Janssen Research and DevelopmentREGN5458: Regeneron PharmaceuticalsIberdomide: CelgeneNY-ESO-1 C259 T Cells: GlaxoSmithKlineBraftovi (encorafenib): PfizerJCARH125: Celgene CorporationFelzartamab (MOR202): I-Mab BiopharmaChidamide (Epidaza): Shenzhen Chipscreen BioscienceThe past couple of decades have shown vast changes in the treatment landscape of Multiple Myeloma, starting with the use of stem cells trailed by the availability of novel treatments such as immunomodulators and proteasome inhibitors that have transformed the natural history of the indication, leading to increased survival times.
